- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02246816
A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001
February 16, 2015 updated by: Marathon Pharmaceuticals, LLC
A Phase 3, Open Label Extension Study for Subjects That Complete Study MP-101-CL-001
MP-101 will be evaluated in this study to see if it is safe and tolerable.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University Feinberg School of Medicine
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
Lima, Ohio, United States, 45801
- Regional Infectious Disease Infusion Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37212-1150
- Vanderbilt Center for Human Nutrition
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Be male or female adults, 18 years of age or older
- Have SBS that is inadequately controlled on current antidiarrheal medication (e.g., loperamide or diphenoxylate), including subjects with ileostomies
- Must have been deemed a completer of study protocol MP-101-CL-001.
- Males or non-pregnant, non-lactating females who are postmenopausal, naturally or surgically sterile, or who agree to use effective contraceptive methods throughout the course of the study. Postmenopausal is defined as at least 12 months of natural spontaneous amenorrhea, or at least 6 weeks following surgical menopause (bilateral oophorectomy)
Females of childbearing potential must agree to use 1 of the following acceptable birth control methods:
- Surgically sterile (hysterectomy or bilateral oophorectomy)
- Surgically sterile (bilateral tubal ligation with surgery at least 6 weeks prior to study initiation)
- Intrauterine device (IUD) in place for at least 3 months
- Abstinence (not having sexual intercourse)
- Barrier method (condom or diaphragm) with spermicide for at least 14 days prior to screening and through study completion
- Stable hormonal contraceptive for at least 3 months prior to study and through study completion
- Vasectomized partner
- Females of childbearing potential must have a negative serum human chorionic gonadotropin (hCG) pregnancy test at Visit 1.
- Be able to understand and provide signed informed consent
Exclusion Criteria:
- Have any history of or active neurological, endocrine, cardiovascular, pulmonary, hematological, immunologic, psychiatric, or metabolic disease that is considered clinically significant, is not currently controlled by medication, and is stable as deemed by the Investigator
- Are currently taking antibiotics for bacterial overgrowth
- Have known or suspected pregnancy, planned pregnancy, or lactation
- Have a planned surgery during the course of the study
- Have a condition the Investigator believes would interfere with the ability to provide informed consent or comply with study instructions, or that might confound the interpretation of the study results or put the subject at undue risk
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: All Subjects
Assigned to receive open-label 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
|
0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants with Adverse Events
Time Frame: Up to 120 Days
|
Up to 120 Days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2015
Primary Completion (Anticipated)
February 1, 2018
Study Completion (Anticipated)
February 1, 2018
Study Registration Dates
First Submitted
September 19, 2014
First Submitted That Met QC Criteria
September 22, 2014
First Posted (Estimate)
September 23, 2014
Study Record Updates
Last Update Posted (Estimate)
February 18, 2015
Last Update Submitted That Met QC Criteria
February 16, 2015
Last Verified
November 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Postoperative Complications
- Disease
- Gastrointestinal Diseases
- Intestinal Diseases
- Malabsorption Syndromes
- Syndrome
- Short Bowel Syndrome
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Gastrointestinal Agents
- Analgesics, Opioid
- Narcotics
- Respiratory System Agents
- Antitussive Agents
- Antidiarrheals
- Opium
Other Study ID Numbers
- MP-101-CL-002OLE
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Short Bowel Syndrome
-
Marathon Pharmaceuticals, LLCWithdrawnShort Bowel Syndrome | Short Gut Syndrome | SBS | Short Gut | Short BowelUnited States
-
Central Hospital, Nancy, FranceBeaujon Hospital; Société Francophone Nutrition Clinique et MétabolismeUnknownSBS - Short Bowel SyndromeFrance
-
TakedaRecruitingShort Bowel Syndrome (SBS)Canada
-
GlyPharma TherapeuticsVectivBio AGCompletedSBS - Short Bowel SyndromeDenmark
-
TakedaCompletedShort Bowel Syndrome (SBS)Brazil
-
ShireRecruitingShort Bowel Syndrome (SBS)United States
-
University of Texas Southwestern Medical CenterChildren's Hospital of PhiladelphiaNot yet recruitingShort Gut Syndrome
-
Children's Hospital of PhiladelphiaUniversity of PennsylvaniaRecruiting
-
University of MiamiQOL Medical, LLCRecruitingShort Gut SyndromeUnited States
-
Wake Forest UniversityCompletedPrematurity | Short Bowel Syndrome (SBS) | Necrotizing Enterocolitis (NEC) | Intestine PerforationUnited States